| Year |
Citation |
Score |
| 2022 |
Dorval L, Knapp BI, Majekodunmi OA, Eliseeva S, Bidlack JM. Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence. Neuropharmacology. 202: 108858. PMID 34715121 DOI: 10.1016/j.neuropharm.2021.108858 |
0.413 |
|
| 2020 |
Bartlett MJ, Mabrouk OS, Szabò L, Flores AJ, Parent KL, Bidlack JM, Heien ML, Kennedy RT, Polt R, Sherman SJ, Falk T. The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia. International Journal of Molecular Sciences. 22. PMID 33374986 DOI: 10.3390/ijms22010020 |
0.435 |
|
| 2020 |
Barnett ME, Knapp BI, Bidlack JM. Unique Pharmacological Properties of the Kappa Opioid Receptor Signaling Through Gz as Shown with Bioluminescence Resonance Energy Tranfer. Molecular Pharmacology. 98: 462-474. PMID 32958572 DOI: 10.1124/mol.120.119404 |
0.568 |
|
| 2020 |
Stevenson GW, Giuvelis D, Cormier J, Cone K, Atherton P, Krivitsky R, Warner E, St Laurent B, Dutra J, Bidlack JM, Szabò L, Polt R, Bilsky EJ. Behavioral pharmacology of the mixed-action delta-selective opioid receptor agonist BBI-11008: studies on acute, inflammatory and neuropathic pain, respiration, and drug self-administration. Psychopharmacology. PMID 31912192 DOI: 10.1007/S00213-019-05449-Z |
0.393 |
|
| 2018 |
Bidlack JM, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Wonsey AM, Toh MF, Pin SS, Namchuk MN. Pharmacological Characterization of Buprenorphine, Samidorphan, and Combinations Being Developed as an Adjunctive Treatment for Major Depressive Disorder. The Journal of Pharmacology and Experimental Therapeutics. PMID 30108159 DOI: 10.1124/jpet.118.249839 |
0.449 |
|
| 2018 |
Bidlack J, Knapp BI, Deaver DR, Plotnikava M, Arnelle D, Quinn AM, Toh MF, Pin SS, Namchuk MN. S165. ALKS 5461: Affinity, Potency, and Functional Activity of Buprenorphine and Samidorphan Alone and in Combination Biological Psychiatry. 83: S412. DOI: 10.1016/J.Biopsych.2018.02.1057 |
0.333 |
|
| 2017 |
Callaghan CK, Rouine J, Dean RL, Knapp BI, Bidlack JM, Deaver DR, O'Mara SM. Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model. Brain, Behavior, and Immunity. PMID 28844812 DOI: 10.1016/J.Bbi.2017.08.016 |
0.375 |
|
| 2015 |
Lefever M, Li Y, Anglin B, Muthu D, Giuvelis D, Lowery JJ, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Structural Requirements for CNS Active Opioid Glycopeptides. Journal of Medicinal Chemistry. 58: 5728-41. PMID 26125201 DOI: 10.1021/Acs.Jmedchem.5B00014 |
0.419 |
|
| 2014 |
Li Y, St Louis L, Knapp BI, Muthu D, Anglin B, Giuvelis D, Bidlack JM, Bilsky EJ, Polt R. Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin? Journal of Medicinal Chemistry. 57: 2237-46. PMID 24576160 DOI: 10.1021/Jm400879W |
0.46 |
|
| 2014 |
Bidlack JM. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence. Advances in Pharmacology (San Diego, Calif.). 69: 387-418. PMID 24484983 DOI: 10.1016/B978-0-12-420118-7.00010-X |
0.497 |
|
| 2014 |
Sromek AW, Provencher BA, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL. Preliminary pharmacological evaluation of enantiomeric morphinans. Acs Chemical Neuroscience. 5: 93-9. PMID 24393077 DOI: 10.1021/Cn400205Z |
0.539 |
|
| 2014 |
Knapp B, Bidlack JM. Activation of G-protein and c-Jun N-terminal kinase by kappa opioid receptor ligands Drug and Alcohol Dependence. 140: e106. DOI: 10.1016/j.drugalcdep.2014.02.306 |
0.478 |
|
| 2014 |
Bidlack JM, Knapp B, Sromek A, Neumeyer J. A mixed kappa/mu partial opioid agonist attenuated cocaine-induced locomotion Drug and Alcohol Dependence. 140: e14. DOI: 10.1016/J.DRUGALCDEP.2014.02.059 |
0.418 |
|
| 2013 |
Provencher BA, Sromek AW, Li W, Russell S, Chartoff E, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors. Journal of Medicinal Chemistry. 56: 8872-8. PMID 24107104 DOI: 10.1021/Jm401290Y |
0.605 |
|
| 2013 |
VanAlstine MA, Wentland MP, Alvarez J, Cao Q, Cohen DJ, Knapp BI, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 9: Synthesis, characterization and molecular modeling of pyridinyl isosteres of N-BPE-8-CAC (1), a high affinity ligand for opioid receptors. Bioorganic & Medicinal Chemistry Letters. 23: 2128-33. PMID 23434225 DOI: 10.1016/J.Bmcl.2013.01.117 |
0.482 |
|
| 2013 |
Hoot MR, Sypek EI, Reilley KJ, Carey AN, Bidlack JM, McLaughlin JP. Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward. Behavioural Pharmacology. 24: 144-52. PMID 23412114 DOI: 10.1097/Fbp.0B013E32835F3D2F |
0.759 |
|
| 2012 |
Wentland MP, Jo S, Gargano JM, VanAlstine MA, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar Ki range: oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC. Bioorganic & Medicinal Chemistry Letters. 22: 7340-4. PMID 23142613 DOI: 10.1016/J.Bmcl.2012.10.081 |
0.479 |
|
| 2012 |
Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. Journal of Medicinal Chemistry. 55: 3878-90. PMID 22439881 DOI: 10.1021/Jm3001086 |
0.441 |
|
| 2012 |
Li Y, Lefever MR, Muthu D, Bidlack JM, Bilsky EJ, Polt R. Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins. Future Medicinal Chemistry. 4: 205-26. PMID 22300099 DOI: 10.4155/Fmc.11.195 |
0.367 |
|
| 2012 |
Dean RL, Eyerman D, Todtenkopf MS, Turncliff RZ, Bidlack JM, Deaver DR. Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. Pharmacology, Biochemistry, and Behavior. 100: 530-7. PMID 22056608 DOI: 10.1016/j.pbb.2011.10.019 |
0.465 |
|
| 2011 |
Yeomans L, Muthu D, Lowery JJ, Martinez HN, Abrell L, Lin G, Strom K, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments. Chemical Biology & Drug Design. 78: 749-56. PMID 21801311 DOI: 10.1111/J.1747-0285.2011.01203.X |
0.323 |
|
| 2011 |
Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors. Bioorganic & Medicinal Chemistry. 19: 2808-16. PMID 21482470 DOI: 10.1016/J.Bmc.2011.03.052 |
0.515 |
|
| 2011 |
Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL. Aminothiazolomorphinans with mixed κ and μ opioid activity. Journal of Medicinal Chemistry. 54: 1903-13. PMID 21351746 DOI: 10.1021/Jm101542C |
0.539 |
|
| 2011 |
Hough LB, Nalwalk JW, Yang J, Conroy JL, VanAlstine MA, Yang W, Gargano J, Shan Z, Zhang SZ, Wentland MP, Phillips JG, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, et al. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain. 152: 878-87. PMID 21316152 DOI: 10.1016/J.Pain.2011.01.001 |
0.309 |
|
| 2011 |
Balboni G, Salvadori S, Marczak ED, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Si YG, Neumeyer JL. Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. European Journal of Medicinal Chemistry. 46: 799-803. PMID 21216504 DOI: 10.1016/j.ejmech.2010.12.001 |
0.559 |
|
| 2011 |
Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ. In vivo characterization of MMP-2200, a mixed δ/μ opioid agonist, in mice. The Journal of Pharmacology and Experimental Therapeutics. 336: 767-78. PMID 21118955 DOI: 10.1124/Jpet.110.172866 |
0.5 |
|
| 2010 |
Balboni G, Salvadori S, Trapella C, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Neumeyer JL. Evolution of the Bifunctional Lead μ Agonist / δ Antagonist Containing the Dmt-Tic Opioid Pharmacophore. Acs Chemical Neuroscience. 1: 155-164. PMID 20352071 DOI: 10.1021/cn900025j |
0.503 |
|
| 2010 |
Fulton BS, Knapp BL, Bidlack JM, Neumeyer JL. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorganic & Medicinal Chemistry Letters. 20: 1507-9. PMID 20144870 DOI: 10.1016/j.bmcl.2010.01.101 |
0.586 |
|
| 2010 |
Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, Mazurkiewicz JE, Snyder-Keller A, Shan Z, Zhang SZ, Wentland MP, Behr M, ... ... Bidlack JM, et al. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nature Neuroscience. 13: 284-6. PMID 20139973 DOI: 10.1038/Nn.2497 |
0.329 |
|
| 2010 |
Decker M, Si YG, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. Journal of Medicinal Chemistry. 53: 402-18. PMID 19928862 DOI: 10.1021/jm9013482 |
0.518 |
|
| 2010 |
Neumeyer JL, Gu X, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM. ChemInform Abstract: Mixed ϰ Agonists and μ Agonists/Antagonists as Potential Pharmacotherapeutics for Cocaine Abuse: Synthesis and Opioid Receptor Binding Affinity of N-Substituted Derivatives of Morphinan. Cheminform. 33: no-no. DOI: 10.1002/CHIN.200204221 |
0.505 |
|
| 2010 |
Wentland MP, Lou R, Dehnhardt CM, Duan W, Cohen DJ, Bidlack JM. ChemInform Abstract: 3-Carboxamido Analogues of Morphine and Naltrexone: Synthesis and Opioid Receptor Binding Properties. Cheminform. 32: no-no. DOI: 10.1002/CHIN.200147180 |
0.593 |
|
| 2010 |
Schultz AG, Guzi TJ, Larsson E, Rahm R, Thakkar K, Bidlack JM. ChemInform Abstract: Preparation and Diastereoselective Birch Reduction-Alkylation of Chiral 3,4-Dihydro-1(2H)-isoquinolinones. Enantiospecific Syntheses and Opioid Receptor Affinities of Several Hydro-2,3-dimethyl-1H-7,12a-methanobenzo[6,7]cycloocta [1,2 Cheminform. 30: no-no. DOI: 10.1002/chin.199912226 |
0.381 |
|
| 2010 |
HUTCHINSON I, ARCHER S, HILL KP, BIDLACK JM. ChemInform Abstract: Synthesis and Opioid Binding Properties of 2-Chloroacrylamido Derivatives of 7,8-Dihydromorphinans. Cheminform. 27: no-no. DOI: 10.1002/chin.199648239 |
0.45 |
|
| 2010 |
SCHULTZ AG, WANG A, ALVA C, SEBASTIAN A, GLICK SD, DEECHER DC, BIDLACK JM. ChemInform Abstract: Asymmetric Syntheses, Opioid Receptor Affinities, and Antinociceptive Effects of 8-Amino-5,9-methanobenzocyclooctenes, a New Class of Structural Analogues of the Morphine Alkaloids. Cheminform. 27: no-no. DOI: 10.1002/chin.199635221 |
0.549 |
|
| 2009 |
Decker M, Fulton BS, Zhang B, Knapp BI, Bidlack JM, Neumeyer JL. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. Journal of Medicinal Chemistry. 52: 7389-96. PMID 19634902 DOI: 10.1021/jm900379p |
0.539 |
|
| 2009 |
Keyari CM, Knapp BI, Bidlack JM, Lowey J, Bilsky EJ, Polt R. Glycosyl-enkephalins: synthesis and binding at the mu, delta & kappa opioid receptors. Antinociception in mice. Advances in Experimental Medicine and Biology. 611: 495-6. PMID 19400281 DOI: 10.1007/978-0-387-73657-0_214 |
0.58 |
|
| 2009 |
Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, Bidlack JM. Syntheses of novel high affinity ligands for opioid receptors. Bioorganic & Medicinal Chemistry Letters. 19: 2289-94. PMID 19282177 DOI: 10.1016/J.Bmcl.2009.02.078 |
0.501 |
|
| 2009 |
Wentland MP, Lu Q, Ganorkar R, Zhang SZ, Jo S, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: Syntheses and opioid receptor properties of cyclic variants of cyclazocine Bioorganic and Medicinal Chemistry Letters. 19: 365-368. PMID 19091564 DOI: 10.1016/J.Bmcl.2008.11.076 |
0.583 |
|
| 2009 |
Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM. Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorganic & Medicinal Chemistry Letters. 19: 203-8. PMID 19027293 DOI: 10.1016/J.Bmcl.2008.10.134 |
0.603 |
|
| 2008 |
Mathews JL, Smrcka AV, Bidlack JM. A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 12183-9. PMID 19020012 DOI: 10.1523/Jneurosci.2326-08.2008 |
0.52 |
|
| 2008 |
Fulton BS, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors. Bioorganic & Medicinal Chemistry Letters. 18: 4474-6. PMID 18674902 DOI: 10.1016/j.bmcl.2008.07.054 |
0.591 |
|
| 2008 |
Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochemical Research. 33: 2142-50. PMID 18528756 DOI: 10.1007/s11064-008-9752-3 |
0.548 |
|
| 2008 |
Wentland MP, Sun X, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine Bioorganic and Medicinal Chemistry. 16: 5653-5664. PMID 18417347 DOI: 10.1016/J.Bmc.2008.03.066 |
0.602 |
|
| 2007 |
VanAlstine MA, Wentland MP, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4′-phenyl)-phenethyl) analogues of 8-CAC Bioorganic and Medicinal Chemistry Letters. 17: 6516-6520. PMID 17935988 DOI: 10.1016/J.Bmcl.2007.09.082 |
0.557 |
|
| 2007 |
Zhang A, Li F, Ding C, Yao Q, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol. Journal of Medicinal Chemistry. 50: 2747-51. PMID 17488103 DOI: 10.1021/jm0701674 |
0.489 |
|
| 2007 |
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorganic & Medicinal Chemistry. 15: 4106-12. PMID 17433695 DOI: 10.1016/j.bmc.2007.03.076 |
0.631 |
|
| 2007 |
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. Journal of Medicinal Chemistry. 50: 2254-8. PMID 17407276 DOI: 10.1021/jm061327z |
0.604 |
|
| 2007 |
Lowery JJ, Yeomans L, Keyari CM, Davis P, Porreca F, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Glycosylation improves the central effects of DAMGO. Chemical Biology & Drug Design. 69: 41-7. PMID 17313456 DOI: 10.1111/J.1747-0285.2007.00462.X |
0.307 |
|
| 2007 |
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. High-affinity carbamate analogues of morphinan at opioid receptors. Bioorganic & Medicinal Chemistry Letters. 17: 1508-11. PMID 17276685 DOI: 10.1016/j.bmcl.2007.01.013 |
0.557 |
|
| 2006 |
Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM. Opioid receptors and signaling on cells from the immune system. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. 1: 260-9. PMID 18040803 DOI: 10.1007/S11481-006-9026-2 |
0.753 |
|
| 2006 |
Neumeyer JL, Peng X, Knapp BI, Bidlack JM, Lazarus LH, Salvadori S, Trapella C, Balboni G. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. Journal of Medicinal Chemistry. 49: 5640-3. PMID 16942040 DOI: 10.1021/jm0605785 |
0.445 |
|
| 2006 |
Wentland MP, VanAlstine M, Kucejko R, Lou R, Cohen DJ, Parkhill AL, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3- benzazocines. 4. Opioid receptor binding properties of 8-[n-(4′-phenyl)- phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine Journal of Medicinal Chemistry. 49: 5635-5639. PMID 16942039 DOI: 10.1021/Jm060278N |
0.794 |
|
| 2006 |
Nefzi A, Ostresh JM, Appel JR, Bidlack J, Dooley CT, Houghten RA. Identification of potent and highly selective chiral tri-amine and tetra-amine mu opioid receptors ligands: an example of lead optimization using mixture-based libraries. Bioorganic & Medicinal Chemistry Letters. 16: 4331-8. PMID 16750366 DOI: 10.1016/J.Bmcl.2006.05.053 |
0.504 |
|
| 2006 |
Parkhill AL, Bidlack JM. Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50,488 in a mouse monocyte-like cell line. International Immunopharmacology. 6: 1013-9. PMID 16644488 DOI: 10.1016/J.Intimp.2006.01.012 |
0.771 |
|
| 2006 |
Bonacci TM, Mathews JL, Yuan C, Lehmann DM, Malik S, Wu D, Font JL, Bidlack JM, Smrcka AV. Differential targeting of Gbetagamma-subunit signaling with small molecules. Science (New York, N.Y.). 312: 443-6. PMID 16627746 DOI: 10.1126/Science.1120378 |
0.333 |
|
| 2006 |
Sun B, Tipton CM, Bidlack JM. The expression of prodynorphin gene is down-regulated by activation with lipopolysaccharide in U-937 macrophage cells. Journal of Neuroimmunology. 174: 52-62. PMID 16483672 DOI: 10.1016/J.Jneuroim.2006.01.006 |
0.636 |
|
| 2006 |
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. Journal of Medicinal Chemistry. 49: 256-62. PMID 16392810 DOI: 10.1021/jm050577x |
0.597 |
|
| 2005 |
Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. The Journal of Pharmacology and Experimental Therapeutics. 315: 821-7. PMID 16076937 DOI: 10.1124/jpet.105.084343 |
0.626 |
|
| 2005 |
Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 2254-62. PMID 15988468 DOI: 10.1038/Sj.Npp.1300811 |
0.596 |
|
| 2005 |
Wentland MP, Sun X, Bu Y, Lou R, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine. Bioorganic & Medicinal Chemistry Letters. 15: 2547-51. PMID 15863314 DOI: 10.1016/J.Bmcl.2005.03.056 |
0.416 |
|
| 2005 |
Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorganic & Medicinal Chemistry Letters. 15: 2107-10. PMID 15808478 DOI: 10.1016/J.Bmcl.2005.02.032 |
0.542 |
|
| 2004 |
Zhen Z, Bradel-Tretheway BG, Dewhurst S, Bidlack JM. Transient overexpression of kappa and mu opioid receptors using recombinant adenovirus vectors. Journal of Neuroscience Methods. 136: 133-9. PMID 15183265 DOI: 10.1016/J.Jneumeth.2004.01.009 |
0.552 |
|
| 2004 |
Csutoras C, Zhang A, Bidlack JM, Neumeyer JL. An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors. Bioorganic & Medicinal Chemistry. 12: 2687-90. PMID 15110850 DOI: 10.1016/j.bmc.2004.03.011 |
0.364 |
|
| 2004 |
Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL. 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols. Journal of Medicinal Chemistry. 47: 1886-8. PMID 15055988 DOI: 10.1021/jm049978n |
0.517 |
|
| 2004 |
Rusovici DE, Negus SS, Mello NK, Bidlack JM. Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans. European Journal of Pharmacology. 485: 119-25. PMID 14757131 DOI: 10.1016/J.Ejphar.2003.11.078 |
0.595 |
|
| 2004 |
Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI, Wentland MP, Neumeyer JL. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. Journal of Medicinal Chemistry. 47: 165-74. PMID 14695830 DOI: 10.1021/Jm0304156 |
0.547 |
|
| 2004 |
Bidlack JM, Parkhill AL. Assay of G protein-coupled receptor activation of G proteins in native cell membranes using [35S]GTP gamma S binding. Methods in Molecular Biology (Clifton, N.J.). 237: 135-43. PMID 14501046 DOI: 10.1385/1-59259-430-1:135 |
0.763 |
|
| 2003 |
Neumeyer JL, Zhang A, Xiong W, Gu XH, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. Journal of Medicinal Chemistry. 46: 5162-70. PMID 14613319 DOI: 10.1021/Jm030139V |
0.49 |
|
| 2003 |
Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, Glick SD, Bidlack JM. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. Journal of Medicinal Chemistry. 46: 2716-30. PMID 12801235 DOI: 10.1021/Jm020562O |
0.426 |
|
| 2003 |
Wentland MP, Sun X, Ye Y, Lou R, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-Formamidocyclazocine analogues Bioorganic and Medicinal Chemistry Letters. 13: 1911-1914. PMID 12749896 DOI: 10.1016/S0960-894X(03)00295-6 |
0.387 |
|
| 2003 |
Wentland MP, Ye Y, Cioffi CL, Lou R, Zhou Q, Xu G, Duan W, Dehnhardt CM, Sun X, Cohen DJ, Bidlack JM. Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines Journal of Medicinal Chemistry. 46: 838-849. PMID 12593663 DOI: 10.1021/Jm020429W |
0.584 |
|
| 2002 |
Parkhill AL, Bidlack JM. Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor. European Journal of Pharmacology. 451: 257-64. PMID 12242086 DOI: 10.1016/S0014-2999(02)02241-0 |
0.807 |
|
| 2002 |
Bidlack JM, Cohen DJ, McLaughlin JP, Lou R, Ye Y, Wentland MP. 8-Carboxamidocyclazocine: A long-acting, novel benzomorphan Journal of Pharmacology and Experimental Therapeutics. 302: 374-380. PMID 12065740 DOI: 10.1124/Jpet.302.1.374 |
0.737 |
|
| 2002 |
Suzuki S, Chuang LF, Doi RH, Bidlack JM, Chuang RY. Kappa-opioid receptors on lymphocytes of a human lymphocytic cell line: morphine-induced up-regulation as evidenced by competitive RT-PCR and indirect immunofluorescence. International Immunopharmacology. 1: 1733-42. PMID 11562065 DOI: 10.1016/S1567-5769(01)00083-2 |
0.596 |
|
| 2001 |
Bidlack JM, Abraham MK. Mitogen-induced activation of mouse T cells increases kappa opioid receptor expression Advances in Experimental Medicine and Biology. 493: 103-110. PMID 11727755 DOI: 10.1007/0-306-47611-8_12 |
0.508 |
|
| 2001 |
Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorganic & Medicinal Chemistry Letters. 11: 2735-40. PMID 11591513 DOI: 10.1016/S0960-894X(01)00543-1 |
0.574 |
|
| 2001 |
Wentland MP, Lou R, Dehnhardt CM, Duan W, Cohen DJ, Bidlack JM. 3-Carboxamido analogues of morphine and naltrexone: Synthesis and opioid receptor binding properties Bioorganic and Medicinal Chemistry Letters. 11: 1717-1721. PMID 11425545 DOI: 10.1016/S0960-894X(01)00278-5 |
0.601 |
|
| 2001 |
Martin-Kleiner I, Bidlack JM. Chronic opioid treatment of the mouse thymoma cell lines R1.G1 and R1EGO leads to down-regulation of the kappa opioid receptor without desensitization of adenylyl cyclase activity. International Immunopharmacology. 1: 13-20. PMID 11367510 DOI: 10.1016/S1567-5769(00)00011-4 |
0.557 |
|
| 2001 |
Wentland MP, Lou R, Ye Y, Cohen DJ, Richardson GP, Bidlack JM. 8-Carboxamidocyclazocine analogues: Redefining the structure-activity relationships of 2,6-methano-3-benzazocines Bioorganic and Medicinal Chemistry Letters. 11: 623-626. PMID 11266156 DOI: 10.1016/S0960-894X(01)00014-2 |
0.475 |
|
| 2000 |
Wentland MP, Duan W, Cohen DJ, Bidlack JM. Selective protection and functionalization of morphine: Synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives Journal of Medicinal Chemistry. 43: 3558-3565. PMID 11000010 DOI: 10.1021/Jm000119I |
0.537 |
|
| 2000 |
Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clinical and Diagnostic Laboratory Immunology. 7: 719-23. PMID 10973443 DOI: 10.1128/CDLI.7.5.719-723.2000 |
0.503 |
|
| 2000 |
Bidlack JM, Jadrovski I. Pharmacological profiles of kappa opioids. Correlation between [35S]GTP gamma S binding and cyclic AMP production. Annals of the New York Academy of Sciences. 909: 264. PMID 10911937 DOI: 10.1111/J.1749-6632.2000.TB06689.X |
0.449 |
|
| 2000 |
Bidlack JM, McLaughlin JP, Wentland MP. Partial opioids. Medications for the treatment of pain and drug abuse Annals of the New York Academy of Sciences. 909: 1-11. PMID 10911920 DOI: 10.1111/J.1749-6632.2000.Tb06672.X |
0.704 |
|
| 2000 |
Neumeyer JL, Mello NK, Negus SS, Bidlack JM. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharmaceutica Acta Helvetiae. 74: 337-44. PMID 10812979 DOI: 10.1016/S0031-6865(99)00044-8 |
0.488 |
|
| 2000 |
Wentland MP, Xu G, Cioffi CL, Ye Y, Duan W, Cohen DJ, Colasurdo AM, Bidlack JM. 8-Aminocyclazocine analogues: Synthesis and structure-activity relationships Bioorganic and Medicinal Chemistry Letters. 10: 183-187. PMID 10673107 DOI: 10.1016/S0960-894X(99)00670-8 |
0.389 |
|
| 2000 |
Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, Mello NK. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. Journal of Medicinal Chemistry. 43: 114-22. PMID 10633042 DOI: 10.1021/Jm9903343 |
0.461 |
|
| 1999 |
Xie W, Samoriski GM, McLaughlin JP, Romoser VA, Smrcka A, Hinkle PM, Bidlack JM, Gross RA, Jiang H, Wu D. Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids. Proceedings of the National Academy of Sciences of the United States of America. 96: 10385-90. PMID 10468617 DOI: 10.1073/Pnas.96.18.10385 |
0.648 |
|
| 1999 |
Martin-Kleiner I, Bidlack JM. The synthetic kappa-opioid agonist (-)U50,488 does not affect calcium transport into R1.1 mouse thymoma cell line. International Journal of Immunopharmacology. 21: 133-40. PMID 10230876 DOI: 10.1016/S0192-0561(98)00075-7 |
0.325 |
|
| 1998 |
Dooley CT, Ny P, Bidlack JM, Houghten RA. Selective ligands for the mu, delta, and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library. The Journal of Biological Chemistry. 273: 18848-56. PMID 9668060 DOI: 10.1074/jbc.273.30.18848 |
0.498 |
|
| 1998 |
Ignatowski TA, Bidlack JM. Changes in KAPPA opioid receptor expression during maturation of mouse lymphocytes Advances in Experimental Medicine and Biology. 437: 117-124. PMID 9666263 DOI: 10.1007/978-1-4615-5347-2_13 |
0.512 |
|
| 1998 |
Sharp BM, Roy S, Bidlack JM. Evidence for opioid receptors on cells involved in host defense and the immune system Journal of Neuroimmunology. 83: 45-56. DOI: 10.1016/S0165-5728(97)00220-8 |
0.588 |
|
| 1997 |
McLaughlin JP, Sebastian A, Archer S, Bidlack JM. 14β-Chlorocinnamoylamino derivatives of metopon: Long-term μ-opioid receptor antagonists European Journal of Pharmacology. 320: 121-129. PMID 9059844 DOI: 10.1016/S0014-2999(96)00904-1 |
0.705 |
|
| 1997 |
Lawrence DM, Hutchinson I, Seyed-Mozaffari A, Archer S, Bidlack JM. Fluorescent staining of kappa opioid receptors using naltrexamine derivatives and phycoerythrin. Journal of Immunological Methods. 201: 173-81. PMID 9050939 DOI: 10.1016/S0022-1759(96)00223-2 |
0.552 |
|
| 1997 |
Pechulis AD, Archer S, Wentland MP, Colasurdo AM, Bidlack JM. Arylacetamide kappa-selective opioid ligands Bioorganic & Medicinal Chemistry Letters. 7: 2271-2276. DOI: 10.1016/S0960-894X(97)00406-X |
0.471 |
|
| 1997 |
Martin-Kleiner I, Bidlack JM. Chronic opioid treatment leads to down-regulation of the kappa-opioid receptors without desensitizing on mouse thymoma cell lines Immunology Letters. 56: 472. DOI: 10.1016/S0165-2478(97)88935-3 |
0.55 |
|
| 1996 |
Archer S, Glick SD, Bidlack JM. Cyclazocine revisited Neurochemical Research. 21: 1369-1373. PMID 8947927 |
0.337 |
|
| 1996 |
Bidlack JM, Lawrence DMP, Ignatowski TA. Kappa opioid receptors on immune cells as studied by fluorescent ligands Advances in Experimental Medicine and Biology. 402: 13-22. PMID 8787638 DOI: 10.1007/978-1-4613-0407-4_3 |
0.619 |
|
| 1996 |
Chao CC, Gekker G, Hu S, Sheng WS, Shark KB, Bu DF, Archer S, Bidlack JM, Peterson PK. kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proceedings of the National Academy of Sciences of the United States of America. 93: 8051-6. PMID 8755601 DOI: 10.1073/pnas.93.15.8051 |
0.407 |
|
| 1996 |
Schultz AG, Wang A, Alva C, Sebastian A, Glick SD, Deecher DC, Bidlack JM. Asymmetric syntheses, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzocyclooctenes, a new class of structural analogues of the morphine alkaloids. Journal of Medicinal Chemistry. 39: 1956-66. PMID 8642554 DOI: 10.1021/Jm950817G |
0.457 |
|
| 1996 |
Hutchinson I, Archer S, Hill KP, Bidlack JM. Synthesis and opioid binding properties of 2-chloroacrylamido derivatives of 7,8-dihydromorphinans Bioorganic & Medicinal Chemistry Letters. 6: 1563-1566. DOI: 10.1016/S0960-894X(96)00274-0 |
0.462 |
|
| 1996 |
Archer S, Glick SD, Maisonneuve IM, Bidlack JM, Xu JY, Teitler M, Sebastian A, El-Hamouly W, Hutchinson I. Suppression of morphine and cocaine self-administration in rats by a mixed mu antagonist-kappa agonist (N-CBM-TAMO) and a long-acting selective D1 antagonist (AS-300) Bioorganic and Medicinal Chemistry Letters. 6: 1139-1144. DOI: 10.1016/0960-894X(96)00186-2 |
0.356 |
|
| 1995 |
McLaughlin JP, Nowak D, Sebastian A, Schultz AG, Archer S, Bidlack JM. Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors. European Journal of Pharmacology. 294: 201-6. PMID 8788432 DOI: 10.1016/0014-2999(95)00536-6 |
0.664 |
|
| 1995 |
Lawrence DM, el-Hamouly W, Archer S, Leary JF, Bidlack JM. Identification of kappa opioid receptors in the immune system by indirect immunofluorescence. Proceedings of the National Academy of Sciences of the United States of America. 92: 1062-6. PMID 7862634 |
0.558 |
|
| 1995 |
Lawrence DM, Joseph DB, Bidlack JM. Kappa opioid receptors expressed on three related thymoma cell lines. Differences in receptor-effector coupling. Biochemical Pharmacology. 49: 81-9. PMID 7840787 DOI: 10.1016/0006-2952(94)00440-W |
0.403 |
|
| 1995 |
Bidlack JM, Joseph DB, Lawrence DM. Kappa opioid receptors on three related thymoma cell lines. Differences in receptor-effector coupling. Advances in Experimental Medicine and Biology. 373: 23-7. PMID 7668156 DOI: 10.1007/978-1-4615-1951-5_4 |
0.532 |
|
| 1995 |
Lawrence DM, Archer S, Bidlack JM. Identification of opioid receptors in the immune system using a novel combination of selective opioid ligands and indirect phycoerythrin immunofluorescence. Advances in Experimental Medicine and Biology. 373: 17-21. PMID 7668148 DOI: 10.1007/978-1-4615-1951-5_3 |
0.567 |
|
| 1994 |
Joseph DB, Bidlack JM. The kappa-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site. European Journal of Pharmacology. 267: 1-6. PMID 8206123 DOI: 10.1016/0922-4106(94)90218-6 |
0.497 |
|
| 1994 |
Dooley CT, Chung NN, Wilkes BC, Schiller PW, Bidlack JM, Pasternak GW, Houghten RA. An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. Science (New York, N.Y.). 266: 2019-22. PMID 7801131 DOI: 10.1126/Science.7801131 |
0.504 |
|
| 1994 |
Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM. Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice. European Journal of Pharmacology. 240: 201-6. PMID 7694857 DOI: 10.1016/0014-2999(93)90899-S |
0.517 |
|
| 1994 |
Archer S, Seyed-Mozaffari A, Jiang Q, Bidlack JM. 14 alpha,14' beta-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14 alpha,14' beta-[dithiobis[(2-oxo-2,1- ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties. Journal of Medicinal Chemistry. 37: 1578-85. PMID 7515442 DOI: 10.1021/jm00037a008 |
0.437 |
|
| 1994 |
McLaughlin JP, Sebastian A, Archer S, Bidlack JM. 14β-Chlorocinnamoylamino derivatives of metopon interact differentially with the mu opioid receptor Regulatory Peptides. 54: 187-188. DOI: 10.1016/0167-0115(94)90453-7 |
0.682 |
|
| 1994 |
Lawrence D, Archer S, Bidlack J. Fluorescent labeling of the kappa opioid receptor by indirect immunofluorescence with phycoerythrin Regulatory Peptides. 54: 161-162. DOI: 10.1016/0167-0115(94)90440-5 |
0.574 |
|
| 1994 |
Joseph D, Lawrence D, Bidlack J. Differences in kappa opioid receptor coupling to G proteins and adenylyl cyclase on three related thymoma cell lines Regulatory Peptides. 54: 141-142. DOI: 10.1016/0167-0115(94)90430-8 |
0.575 |
|
| 1994 |
Jiang Q, Seyed-Mozaffari A, Sebastian A, Archer S, Bidlack J. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism Regulatory Peptides. 54: 137-138. DOI: 10.1016/0167-0115(94)90428-6 |
0.585 |
|
| 1994 |
Joseph D, Lawrence D, Saripalli L, Bidlack J. Chronic opioid treatment of R1.1 cells results in the downregulation of the kappa opioid receptor without desensitization of adenylyl cyclase activity Regulatory Peptides. 53: S183-S184. DOI: 10.1016/0167-0115(94)90301-8 |
0.536 |
|
| 1993 |
Bidlack JM, Kaplan RA, Subbramanian RA, Seyed-Mozaffari A, Archer S. Affinity labeling of the mu opioid receptor in bovine striatal membranes with [3H]-14 beta-(bromoacetamido)-7,8-dihydromorphine. Biochemistry. 32: 6703-11. PMID 7687147 DOI: 10.1021/bi00077a025 |
0.411 |
|
| 1993 |
Jiang Q, Sebastian A, Archer S, Bidlack JM. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties. European Journal of Pharmacology. 230: 129-30. PMID 7679076 DOI: 10.1016/0014-2999(93)90423-F |
0.516 |
|
| 1993 |
Bidlack JM, Saripalli LD, Lawrence DM. kappa-Opioid binding sites on a murine lymphoma cell line. European Journal of Pharmacology. 227: 257-65. PMID 1335414 DOI: 10.1016/0922-4106(92)90003-E |
0.433 |
|
| 1993 |
Lawrence DM, Bidlack JM. Kappa opioid binding sites on the R1.1 murine lymphoma cell line: sensitivity to cations and guanine nucleotides. Journal of Neuroimmunology. 41: 223-30. PMID 1334968 DOI: 10.1016/0165-5728(92)90073-T |
0.48 |
|
| 1990 |
Bidlack J. Quantitative Imaging: Neuroreceptors, Neurotransmitters, and Enzymes Archives of Neurology. 47: 1166-1166. DOI: 10.1001/Archneur.1990.00530110018006 |
0.323 |
|
| 1989 |
Selley DE, Bidlack JM. Guanine nucleotide regulation of [125I]beta-endorphin binding to NG108-15 and SK-N-SH cell membranes: specific cation requirements. Brain Research. 493: 23-32. PMID 2550106 DOI: 10.1016/0006-8993(89)90996-7 |
0.381 |
|
| 1989 |
Bidlack JM, Frey DK, Seyed-Mozaffari A, Archer S. 14 beta-(Bromoacetamido)morphine irreversibly labels mu opioid receptors in rat brain membranes. Biochemistry. 28: 4333-9. PMID 2548575 DOI: 10.1021/bi00436a031 |
0.501 |
|
| 1989 |
Hemmick LM, Bidlack JM. Beta-endorphin suppresses rat plaque-forming cell response by a non-opioid mechanism. Journal of Neuroimmunology. 23: 67-71. PMID 2524503 DOI: 10.1016/0165-5728(89)90074-X |
0.362 |
|
| 1988 |
Tyler CB, Bidlack JM. Inhibition of (+)[3H]SKF 10,047 binding to rat brain membranes by FAB fragments from a monoclonal antibody directed against the opioid receptor. Neurochemical Research. 13: 729-35. PMID 2845286 DOI: 10.1007/BF00971595 |
0.47 |
|
| 1988 |
Civelli O, Machida C, Bunzow J, Albert P, Hanneman E, Salon J, Bidlack J, Grandy D. The next frontier in the molecular biology of the opioid system Molecular Neurobiology. 1: 373-392. DOI: 10.1007/978-1-4612-4604-6_13 |
0.596 |
|
| 1987 |
Hemmick LM, Bidlack JM. Beta-endorphin modulation of mitogen-stimulated calcium uptake by rat thymocytes. Life Sciences. 41: 1971-8. PMID 2958669 DOI: 10.1016/0024-3205(87)90750-8 |
0.312 |
|
| 1987 |
Civelli O, Machida C, Bunzow J, Albert P, Hanneman E, Salon J, Bidlack J, Grandy D. The next frontier in the molecular biology of the opioid system. The opioid receptors. Molecular Neurobiology. 1: 373-91. PMID 2855792 DOI: 10.1007/Bf02935742 |
0.614 |
|
| 1984 |
Bidlack JM, Denton RR, Harwell LW. Generating monoclonal antibodies to the opioid receptor. Life Sciences. 151-4. PMID 6319852 DOI: 10.1016/0024-3205(83)90466-6 |
0.315 |
|
| 1982 |
Bidlack JM, Ambudkar IS, Shamoo AE. Purification of phospholamban, a 22,000-dalton protein from cardiac sarcoplasmic reticulum that is specifically phosphorylated by cyclic AMP-dependent protein kinase. The Journal of Biological Chemistry. 257: 4501-6. PMID 6121803 DOI: 10.2172/5008458 |
0.492 |
|
| 1981 |
Bidlack JM, Abood LG, Osei-Gyimah P, Archer S. Purification of the opiate receptor from rat brain. Proceedings of the National Academy of Sciences of the United States of America. 78: 636-9. PMID 6264453 DOI: 10.1073/pnas.78.1.636 |
0.404 |
|
| 1980 |
Bidlack JM, Shamoo AE. Adenosine 3',5'-monophosphate-dependent phosphorylation of a 6000 and a 22,000 dalton protein from cardiac sarcoplasmic reticulum. Biochimica Et Biophysica Acta. 632: 310-25. PMID 6251912 DOI: 10.1016/0304-4165(80)90089-6 |
0.503 |
|
| 1980 |
Bidlack JM, Abood LG. Solubilization of the opiate receptor. Life Sciences. 27: 331-40. PMID 6251330 DOI: 10.1016/0024-3205(80)90201-5 |
0.448 |
|
| Show low-probability matches. |
